Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

ROR1-Directed Chimeric Antigen Receptor T Cell Recognition of Self-Antigen Is Associated with Acute Toxicity, T Cell Dysfunction, and Poor Tumor Control.

James B Rottman, DVM, PhD DACVP, Kenneth Ganley, BS, Brenna Daly, BS, Holly M. Horton, PhD, Kevin M. Friedman, Molly Perkins, PhD, Shannon Grande, PhD, Claire J Rhodes, BS, Richard A. Morgan, PhD, Christopher J. Horvath, DVM, MS, DACVP

Blood (2017) 130 (Supplement 1): 4450.

https://doi.org/10.1182/blood.V130.Suppl_1.4450.4450

Published: 2017

Journal Articles

Manufacturing an Enhanced CAR T Cell Product By Inhibition of the PI3K/Akt Pathway During T Cell Expansion Results in Improved In Vivo Efficacy of Anti-BCMA CAR T Cells

Molly R. Perkins, D.Phil., Shannon Grande, PhD, Amanda Hamel, BS, Holly M. Horton, PhD, Tracy E. Garrett, BA, Sara M. Miller, Howard J. Latimer, IV, BS, Christopher J. Horvath, DVM, MS, DACVP, Michael Kuczewski, MS, Kevin M. Friedman, PhD, Richard A. Morgan, PhD

Blood (2015) 126 (23): 1893.

https://doi.org/10.1182/blood.V126.23.1893.1893

Published: 2015

Journal Articles

A Novel and Highly Potent CAR T Cell Drug Product for Treatment of BCMA-Expressing Hematological Malignances

Alena A. Chekmasova, PhD, Holly M. Horton, PhD, Tracy E. Garrett, BA, John W. Evans, PhD, Johanna Griecci, BS, Amanda Hamel, BS, Howard J. Latimer, IV, BS, Stacie L. Seidel, MA, Byoung Y. Ryu, PhD, Michael Kuczewski, MS, Christopher J. Horvath, DVM, MS, DACVP, Kevin M. Friedman, PhD, Richard A. Morgan, PhD

Blood (2015) 126 (23): 3094.

https://doi.org/10.1182/blood.V126.23.3094.3094

Published: 2015

Journal Articles

C3-Mediated Extravascular Hemolysis In Paroxysmal Nocturnal Hemoglobinuria: An In Vitro Model to Dissect Complement C3 Activation Comparing the Effects of Complement Inhibitors Eculizumab, 3E7 and TT30 on C3 Fragment Processing and Hemolysis of PNH Erythrocytes

Antonio M. Risitano, MD, PhD, Caterina Pascariello, Luigi Del Vecchio, MD, Christopher J Horvath, DVM, MS, DACVP, Masha Fridkis-Hareli, PhD, V. Michael Holers, MD, Margaret A Lindorfer, PhD, Ronald P Taylor, PhD

Blood (2010) 116 (21): 637.

https://doi.org/10.1182/blood.V116.21.637.637

Published: 2010

Journal Articles

TT30, a Novel Human Complement Inhibitor in Development for Paroxysmal Nocturnal Hemoglobinuria and Other Hemolytic Disorders, Demonstrates Red Blood Cell Surface Targeting and Retention In a Model of Complement Alternative Pathway-Mediated Hemolysis

Masha Fridkis-Hareli, PhD, Michael Storek, PhD, Antonio M. Risitano, MD, PhD, Ante S. Lundberg, MD, Christopher J Horvath, DVM, MS, DACVP, V. Michael Holers, MD

Blood (2010) 116 (21): 638.

https://doi.org/10.1182/blood.V116.21.638.638

Published: 2010

Journal Articles

TT30, a Novel Human Protein Therapeutic, Selectively Modulates the Complement Alternative Pathway by Targeted Supplementation of Local Factor H Activity.

V. Michael Holers, Istvan Mazsaroff, PhD, Hillary Akana, Christopher G. Smith, J. Woodruff Emlen, MD, Russell C. Marians, PhD, Christopher J. Horvath, DVM

Blood (2009) 114 (22): 3021.

https://doi.org/10.1182/blood.V114.22.3021.3021

Published: 2009

NARROW

ROR1-Directed Chimeric Antigen Receptor T Cell Recognition of Self-Antigen Is Associated with Acute Toxicity, T Cell Dysfunction, and Poor Tumor Control.

Manufacturing an Enhanced CAR T Cell Product By Inhibition of the PI3K/Akt Pathway During T Cell Expansion Results in Improved In Vivo Efficacy of Anti-BCMA CAR T Cells

A Novel and Highly Potent CAR T Cell Drug Product for Treatment of BCMA-Expressing Hematological Malignances

C3-Mediated Extravascular Hemolysis In Paroxysmal Nocturnal Hemoglobinuria: An In Vitro Model to Dissect Complement C3 Activation Comparing the Effects of Complement Inhibitors Eculizumab, 3E7 and TT30 on C3 Fragment Processing and Hemolysis of PNH Erythrocytes

TT30, a Novel Human Complement Inhibitor in Development for Paroxysmal Nocturnal Hemoglobinuria and Other Hemolytic Disorders, Demonstrates Red Blood Cell Surface Targeting and Retention In a Model of Complement Alternative Pathway-Mediated Hemolysis

TT30, a Novel Human Protein Therapeutic, Selectively Modulates the Complement Alternative Pathway by Targeted Supplementation of Local Factor H Activity.

Email alerts

ASH Publications

American Society of Hematology

ROR1-Directed Chimeric Antigen Receptor T Cell Recognition of Self-Antigen Is Associated with Acute Toxicity, T Cell Dysfunction, and Poor Tumor Control.

Manufacturing an Enhanced CAR T Cell Product By Inhibition of the PI3K/Akt Pathway During T Cell Expansion Results in Improved In Vivo Efficacy of Anti-BCMA CAR T Cells

A Novel and Highly Potent CAR T Cell Drug Product for Treatment of BCMA-Expressing Hematological Malignances

C3-Mediated Extravascular Hemolysis In Paroxysmal Nocturnal Hemoglobinuria: An In Vitro Model to Dissect Complement C3 Activation Comparing the Effects of Complement Inhibitors Eculizumab, 3E7 and TT30 on C3 Fragment Processing and Hemolysis of PNH Erythrocytes

TT30, a Novel Human Complement Inhibitor in Development for Paroxysmal Nocturnal Hemoglobinuria and Other Hemolytic Disorders, Demonstrates Red Blood Cell Surface Targeting and Retention In a Model of Complement Alternative Pathway-Mediated Hemolysis

TT30, a Novel Human Protein Therapeutic, Selectively Modulates the Complement Alternative Pathway by Targeted Supplementation of Local Factor H Activity.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only